Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Aclaris Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 5.50 · gapped above the open, then crossed back over prior close. High/low 5.54 at 2:00 pm ET, 5.43 at 10:45 am ET.
149 institutional managers report a position in Aclaris Therapeutics, Inc. worth $633.0M between them, filed on form 13F for the quarter ending 2026-06-30. 20 of them hold 80% of it, the largest being RA Capital Management, LLC at 10.63%.
124 more managers in the register
20 managers hold 80% of the $633.0M institutional base. The other 129 hold the rest.
Positions as filed with the SEC for the quarter ended Jun 30. A 13F is due 45 days after the quarter closes, so this register is 78 days old and does not move with the price above it.
via RA Capital Management, LLC, Deep Track Capital, LP, Adage Capital Partners GP, L.L.C. +3 more · 10.63% of ACRS, 11.22% of IPSC
via RA Capital Management, LLC, Deep Track Capital, LP, Rock Springs Capital Management LP +2 more · 10.63% of ACRS, 21.58% of COAG
via RA Capital Management, LLC, Deep Track Capital, LP, Jones Hill Capital LP +5 more · 10.63% of ACRS, 10.36% of BCAX
via RA Capital Management, LLC, Vivo Capital, LLC, Adage Capital Partners GP, L.L.C. +1 more · 10.63% of ACRS, 11.47% of OKUR
via Deep Track Capital, LP, RA Capital Management, LLC, Vivo Capital, LLC +1 more · 7.81% of ACRS, 11.26% of LBRX
via RA Capital Management, LLC, Vivo Capital, LLC, Adage Capital Partners GP, L.L.C. +2 more · 10.63% of ACRS, 6.40% of SABS
Managers holding a meaningful stake in ACRS also hold this much of the other company’s institutional base. Managers who hold most of the companies we cover are excluded, because their overlap says nothing about this one in particular. This is how the two are held, not evidence that one moves the other.
ACRS (Aclaris Therapeutics, Inc.) has 1 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: LLY +0.24%, in healthcare.